Ilixadencel

Targeting solid tumors with an off-the-shelf, cell-based immune primer

Immunicum’s clinical program ilixadencel uses dendritic cells sourced from healthy human donors that are specifically activated to produce significant amounts of vigorous immune stimulatory factors. By administration through intratumoral injection, these cells induce a local inflammatory reaction, leading to destruction of tumor cells, and recruitment and activation of the patient’s own dendritic cells into the tumor environment. The recruited dendritic cells will encounter and engulf dying tumor cells, including the full array of tumor specific proteins, called neoantigens, that will act as an antigen source to activate and educate the tumor specific T cells, specifically cytotoxic CD8+ T cells, resulting in a highly personalized and potent anti-tumor response.


Click on the image to view full size

Ilixadencel has been evaluated in clinical trials for a range of solid tumors, including a Phase II MERECA study in kidney cancer and Phase I/II studies in liver cancer and gastrointestinal stromal tumors (GIST). It is currently being evaluated in combination with checkpoint inhibitors in different solid tumors indications in the Phase Ib/II ILIAD study. For more information on ongoing clinical trials please contact us at info@immunicum.com. All ongoing trials are also listed on clinicaltrials.gov.